eResearch Technology, Inc. (ERES)
The Company provides technology and services that enable the pharmaceutical, biotechnology and medical device industries to collect, interpret and distribute cardiac safety and clinical data.
Recs
Recs
Recs
timattox
(99.47)
Submitted: 11/24/2008 12:17:38 PM :
Start Price:
$4.92
ERES Score:
-17.35
HiGrowthLoDebt screen
Recs
tenmiles
(99.99)
Submitted: 10/31/2008 10:47:23 AM :
Start Price:
$6.18
ERES Score:
-24.14
After today's 30% haircut believe ERES is back in the buy zone for patient longs. Strong balance sheet with significant free cash generation; guiding to low teen forward p/e for this grower- buyer at $6.22
Recs
heym0n
(53.72)
Submitted: 6/11/2008 12:12:04 PM :
Start Price:
$15.79
ERES Score:
-47.29
Exceeded analyst earnings estimates for second straight quarter and price-to-cash-flow ratio well above industry average.
Recs
Recs
Grandeed29
(< 20)
Submitted: 5/12/2008 9:20:47 PM :
Start Price:
$16.11
ERES Score:
-44.81
Highlights for the first quarter of 2008 were:
-- Record quarterly net revenues of $33.7 million, including $3.3 million
of net revenues from Covance Cardiac Safety Services, Inc. (CCSS), a
59.7% increase from the first quarter of 2007.
Recs
EMG114
(24.26)
Submitted: 5/6/2008 10:57:24 PM :
Start Price:
$12.79
ERES Score:
-37.04
This company is growing, just look at the trends and reports. Moreover, the pharmaceutical and biotech industries are expanding and could see some considerable earnings in the next few years...
Recs
rexkwondo
(67.52)
Submitted: 7/23/2007 4:03:35 PM :
Start Price:
$10.13
ERES Score:
-18.08
A simple observation; this company is hiring the best people they can get their hands on, yesterday. Translation: business is booming. Also their size in this space makes them an attractive buyout candidate. Finally, they went through some bad times last year which really brought the price down, problems appear to be resolved.
Recs
GaTeek
(< 20)
Submitted: 5/3/2007 6:59:47 PM :
Start Price:
$8.70
ERES Score:
-10.23
lagging EDC / RX services market comps. Has begun recovery.
Recs
CRAZYCAPTAIN
(99.29)
Submitted: 4/13/2007 10:16:29 AM :
Start Price:
$7.75
ERES Score:
-5.47
ERES stands to gain as sponsors are resigned to regulatory guidance and the QT interdisciplinary review team has processed 66 TQT protocols for the nine months ended March 31.
Recs
Zikar
(< 20)
Submitted: 3/13/2007 2:54:37 PM :
Start Price:
$7.46
ERES Score:
-6.04
While their earnings and revenue growth have slowed greatly, they have cash on hand, low debt, and are still posting a profit.
Recs
msamet1
(89.92)
Submitted: 3/7/2007 10:31:59 AM :
Start Price:
$7.41
ERES Score:
-4.94
electronic capture of drug studies will increase efficiency of drug development
Recs
sparkydiver2
(75.37)
Submitted: 2/21/2007 11:03:55 PM :
Start Price:
$7.05
ERES Score:
+2.52
FDA needs help with next generation of technology and drugs, eres will be there.
Recs
seekar
(20.03)
Submitted: 1/28/2007 1:43:40 PM :
Start Price:
$6.62
ERES Score:
+5.68
I think their business is ready for a turn around. They are the market leader in cardiac studies with 44 of the top 50 pharma companies as customers. Competitirs are other small companies and labs of huge organizations. Expect maybe one more bad quarter before revenues and income increases.
Recs
ROSIERMS
(37.65)
Submitted: 12/14/2006 11:46:53 AM :
Start Price:
$6.40
ERES Score:
+9.03
will be coming back
Recs
Recs
rickyroller
(30.46)
Submitted: 11/29/2006 9:00:24 PM :
Start Price:
$6.40
ERES Score:
+7.65
this may have hit bottom around $6
Recs
SmallTimeBigGuy
(< 20)
Submitted: 11/28/2006 1:26:02 PM :
Start Price:
$6.36
ERES Score:
+6.86
Ready for a turnaround. At least short term.
Recs
mdriver78
(< 20)
Submitted: 9/23/2006 1:30:13 AM :
Start Price:
$8.15
ERES Score:
-17.26
Increasing sales to the bottom line?
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 22 1 2 Next »